Online citations, reference lists, and bibliographies.
← Back to Search

Development Of A Protein Microarray Platform For The Multiplex Analysis Of Biomarkers Associated With Rheumatoid Arthritis

T. Urbanowska
Published 2004 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Currently in the drug development process there is a growing awareness of the need to utilise a biomarker strategy which would allow compounds to be developed in a more efficient way with improved safety and pharmacology. Technologies which can evaluate, validate and monitor biomarkers in a cost effective and efficient manner are a necessity if such a biomarker strategy is to be properly implemented. In this thesis the development, validation and implementation of a protein microarray for quantitative and simultaneous analysis of proteins is described. In order to demonstrate the feasibility of this approach, Rheumatoid arthritis (RA) was chosen as a model for proof of concept. Based on the current literature, seven proteins thought to be associated with the development and progression of RA were selected. Initially, a protein microarray was developed on a glass chip treated either with a self assembled monolayer (SAM) of octadecyl phosphoric acid ester (ODP) or with polyL-lysine. SAM showed its superiority over poly-L-lysine by generating more homogenous and less variable spots. However, the process of coating the chip with the SAM was time consuming and expensive. Moreover, assay processing was entirely performed manually and could not be automated without a significant investment of time and resources. As a result, high inter-chip variability was observed preventing sensitive, quantitative and reproducible analysis to be performed. An attempt was, therefore, undertaken to develop an alternative microarray platform. The appearance on the market of long neck tips for antibody printing devices, provided the option of using established polystyrene 96-well plates as the solid support for developing a fully automated microarray format. The development process involved reagent selection, printing protocol optimization, matrix investigation, assay protocol establishment, and detection system evaluation. The robustness and reproducibility of the methodology was investigated using the Food and Drug Administration (FDA) regulatory guidelines for pharmacokinetic assay validation, in which a spike-recovery validation test was elaborated and run overdays. The method was shown to be both quantitative and reproducible, with an assay accuracy between 70-130%, and assay precision less than 30%. Importantly, the working range for each assay covered the relevant physiological concentrations. In addition, protein microarray performance was compared with the classical ELISA approach. Sera collected from a total of 78 individuals representing either rheumatic or healthy patients were measured using both approaches. Correlation coefficients (R2) between the two technologies was calculated for each analyte giving: 0.90 for A, 0.60 for B, 0.93 for C, 0.96 for D, 0.94 for E and 0.95 for F. Finally, the developed protein microarray was used to compare the analyte concentration levels between patients with RA and other rheumatic diseases. Significant differences in the serum concentration of B (p<0.0022), C (p<0.0107), E (p<0.0024) and F (p<0.0057) between RA and other arthritic patients were observed. In conclusion, the obtained results demonstrate the applicability of the developed protein microarray for quantitative and simultaneous analysis of the selected RA-related proteins in clinical samples. It is anticipated that miniaturized and multiplexed immunoassays which allow for the rapid evaluation of multiple analytes in a single sample, will represent a valuable tool for validating and monitoring biomarkers in the drug development process.
This paper references
10.1093/clinchem/44.9.2015
Ligand assays: from electrophoresis to miniaturized microarrays.
R. Ekins (1998)
10.1016/S1357-2725(03)00259-0
Rheumatoid arthritis: regulation of synovial inflammation.
S. Sweeney (2004)
10.1002/PMIC.200300600
Protein microarrays: Promising tools for proteomic research
M. Templin (2003)
10.1016/S0003-2697(02)00442-6
Optimizing antibody immobilization strategies for the construction of protein microarrays.
Paul Peluso (2003)
10.1016/S1367-5931(02)00005-4
Protein chip technology.
H. Zhu (2003)
10.1136/ard.61.9.804
Soluble adhesion molecules (ICAM-1, VCAM-1, and E-selectin) and vascular endothelial growth factor (VEGF) in patients with distinct variants of rheumatoid synovitis
P. Klimiuk (2002)
10.1515/CCLM.2001.032
Simultaneous Detection of Multiple Proteins with an Array-Based Enzyme-Linked Immunosorbent Assay (ELISA) and Enhanced Chemiluminescence (ECL)
R. Huang (2001)
10.1021/AC980959T
A strategy for the generation of surfaces presenting ligands for studies of binding based on an active ester as a common reactive intermediate: a surface plasmon resonance study.
J. Lahiri (1999)
10.1038/nrd1130
Clinical biomarkers in drug discovery and development
Richard Frank (2003)
10.1006/JMBI.1999.3444
Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides.
A. Knappik (2000)
10.1093/CLINCHEM/48.1.121
Antigen microarrays for serodiagnosis of infectious diseases.
L. Mezzasoma (2002)
10.1016/S1074-5521(00)90067-X
Protein microarrays: prospects and problems.
T. Kodadek (2001)
10.1038/nbt0302-225
A perspective on protein microarrays
P. Mitchell (2002)
10.1016/S0022-1759(99)00206-9
The influence of naturally occurring heterophilic anti-immunoglobulin antibodies on direct measurement of serum proteins using sandwich ELISAs.
C. Hennig (2000)
10.2741/STOLL
Protein microarray technology.
M. Templin (2002)
A Pharmaceutical Industry Perspective
D. Shlaes (2004)
10.1097/00002281-199002030-00003
Heat-shock proteins: a link between rheumatoid arthritis and infection?
S. Kaufmann (1990)
10.1016/S1367-5931(00)00170-8
Protein arrays and microarrays.
H. Zhu (2001)
10.1016/0022-1759(80)90230-6
Antibody production by hybridomas.
J. Goding (1980)
10.1038/nature01511
Mass spectrometry-based proteomics
R. Aebersold (2003)
10.1007/978-94-011-1670-1_37
Autoantibodies in rheumatoid arthritis
J. Smolen (1996)
10.1074/mcp.M200001-MCP200
Complementary Profiling of Gene Expression at the Transcriptome and Proteome Levels in Saccharomyces cerevisiae*S
T. J. Griffin (2002)
10.1046/j.1365-2222.2003.01550.x
Microarrayed recombinant allergens for diagnosis of allergy
C. Harwanegg (2003)
10.1186/gb-2001-2-2-research0004
Protein microarrays for highly parallel detection and quantitation of specific proteins and antibodies in complex solutions
B. Haab (2000)
10.1038/256495a0
Continuous cultures of fused cells secreting antibody of predefined specificity
G. Köhler (1975)
10.1007/S00216-003-2088-6
Protein microarrays: new tools for pharmaceutical development
K. D. Kumble (2003)
10.1016/S0968-0004(00)01725-4
Antibodies: indispensable tools for biomedical research.
R. Goldman (2000)
10.1002/PMIC.200300596
Generation of bioreagents for protein chips
Michael L. Phelan (2003)
10.1016/J.TIBTECH.2004.06.005
Biomarker discovery and validation: technologies and integrative approaches.
S. Ilyin (2004)
10.1080/01926230390224656
Toxicogenomics in Drug Development
N. Guerreiro (2003)
10.1093/INFDIS/164.5.1023
Cytokine levels in serum and cerebrospinal fluid in patients with chronic fatigue syndrome and control subjects.
A. Lloyd (1991)
10.1002/ART.1780310816
Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum.
T. Saxne (1988)
10.1126/science.270.5235.467
Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray
M. Schena (1995)
10.1016/J.COPBIO.2003.10.006
Interplay of transcriptomics and proteomics.
Priti S Hegde (2004)
10.1016/S0167-7012(03)00028-9
Quantitative, multiplexed detection of bacterial pathogens: DNA and protein applications of the Luminex LabMAP system.
S. Dunbar (2003)
Antibody-based technologies for target discovery.
R. P. Valle (2003)
10.1006/ABIO.1999.4363
Protein microchips: use for immunoassay and enzymatic reactions.
P. Arenkov (2000)
10.1002/PMIC.200300609
Current status of protein chip development in terms of fabrication and application
S. Seong (2003)
10.1002/j.1460-2075.1991.tb04978.x
Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis.
J. Keffer (1991)
10.1038/nbt0402-359
Multiplexed protein profiling on microarrays by rolling-circle amplification
B. Schweitzer (2002)
10.1016/0731-7085(89)80079-2
Multi-analyte immunoassay.
R. Ekins (1989)
10.1023/A:1007669411738
Bioanalytical Method Validation—A Revisit with a Decade of Progress
V. Shah (2004)
10.1002/ART.1780160121
American rheumatism association
J. L. Decker (1973)
10.1002/PMIC.200300592
Protein microarrays: Molecular profiling technologies for clinical specimens
V. Espina (2003)
10.1126/SCIENCE.278.5338.680
Exploring the metabolic and genetic control of gene expression on a genomic scale.
J. DeRisi (1997)
10.1038/NPG.ELS.0004021
Enzyme-Linked Immunosorbent Assay
S. Paulie (2006)
10.1016/S1535-6108(03)00086-2
Protein microarrays: meeting analytical challenges for clinical applications.
Lance A. Liotta (2003)
10.1136/ard.50.2.71
Pregnancy and its effect on the risk of developing rheumatoid arthritis.
J. Hazes (1991)
Microarray Biochip Technology
M. Schena (2000)
10.1002/1615-9861(200110)1:10<1271::AID-PROT1271>3.0.CO;2-6
Proteomic profiling of the cancer microenvironment by antibody arrays
V. Knezevic (2001)
10.1038/79570
A protein microarray
H. Feng (2000)
10.1016/S0003-2697(02)00257-9
Toward optimized antibody microarrays: a comparison of current microarray support materials.
Philipp Angenendt (2002)
10.1021/AC034563F
Parallel Comparison of Sandwich and Direct Label Assay Protocols on Cytokine Detection Protein Arrays
Y. Li (2003)
Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis.
P. Charles (1999)
10.1038/81576
Analysis of yeast protein kinases using protein chips
H. Zhu (2000)
10.1002/ART.1780380209
Serum cytokines in juvenile rheumatoid arthritis. Correlation with conventional inflammation parameters and clinical subtypes.
H. Mangge (1995)
10.1002/ART.1780310302
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.
F. Arnett (1988)



Semantic Scholar Logo Some data provided by SemanticScholar